Biotech entity
Of the tracked stories, 2 of 2 also mention McKesson, the most common co-covered peer. The 36-day window averages about 0.4 stories each week. Source depth averages 1.5 original sources per story, versus 4.9 across the same-window beat baseline. Their average consequence score of 5 runs below the beat's 6.5 for that window.
Last mentioned: Aug 2, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Of the tracked stories, 2 of 2 also mention McKesson, the most common co-covered peer. The 36-day window averages about 0.4 stories each week. Source depth averages 1.5 original sources per story, versus 4.9 across the same-window beat baseline. Their average consequence score of 5 runs below the beat's 6.5 for that window. The clearest coverage concentration is funding: 1 of 2 stories, with the rest divided among 1 other category. This profile follows 2 Biotech stories mentioning Cardinal Health across the period from June 28, 2026 to August 2, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 158 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Cardinal Health. Shared-story counts are live from our verified record — not editorial picks.
Colorado’s distribution of $12 million to 27 groups from opioid settlement funds is the latest reminder of pharma’s enduring financial and reputational liabilities. The grants, part of a broader $700M+ state settlement, fuel prevention programs while underscoring that litigation costs continue to ripple through the industry.
Source: kjct8.com
Amgen brings a massive $36.8B revenue base and a broad chronic disease pipeline, while NovoCure pushes the frontier with electric‑field cancer therapy. This analysis weighs drug development scale against device‑based oncology innovation for biotech investors.
Source: The Motley Fool · Brendan Coffey (us)
Cardinal Health is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
